


29 May 2025



CURRICULUM VITAE

May 2025

Leonard Stephen Marks, M.D.

CONTACT INFORMATION

UCLA Department of Urology
300 Stein Plaza #339
Wasserman Building
Los Angeles, CA 90095

PHONE: 310.794.3070

FAX: 310.794.0987

CELL: 310.710.3873

EMAIL: lmarks@mednet.ucla.edu

EDUCATION

1974 - 1978	Resident in Urology UCLA Medical Center, Los Angeles, CA
1973 - 1974	Fellow and Post-Doctoral Research Scholar UCLA Department of Surgery/Cedars-Sinai Medical Center, Los Angeles, CA Renal Hypertension Research
1972 - 1973	Resident in General Surgery UCLA/Harbor General Hospital, Torrance, CA
1969 - 1970	Surgical Internship UCLA/Harbor General Hospital, Torrance, CA
1969	Doctor of Medicine (AOA) University of Texas Medical Branch, Galveston, TX
1969	Master of Arts in Physiology University of Texas Medical Branch, Galveston, TX
1965	Bachelors of Arts (Honors) Tulane University, New Orleans, LA



LICENSURE

1972	California Medical License (C-34148)
1969	Texas Medical License (D-6080)

BOARD CERTIFICATION

1980	Diplomat, American Board of Urology
------	-------------------------------------

PROFESSIONAL EXPERIENCE

UCLA Academic Appointments:

2015 - Present	Professor and DeKernion Endowed Chair in Urology
2009 - Present	Professor In-Residence
2003 - 2009	Clinical Professor
1998 - 2003	Clinical Associate Professor
1978 - 1998	Clinical Assistant Professor

Other Appointments:

1992 - 2009	Founding Director Urologic Sciences Research Foundation (501c3), Culver City, CA
1978 - 2009	Urology Private Practice Culver City, CA
1970 - 1972	LCDR, U.S. Public Health Service Norfolk, VA

PROFESSIONAL ACTIVITIES

UCLA Committee Service:

2010 - Present	Clark Center User's Committee
----------------	-------------------------------

2016 Peter Starrett Chair in Medical Education Search Committee

Memberships in Professional Organizations:

1982 - Present Active Member, American Urological Association

2004 - 2002 Founding Member, American Urologic Association
Complementary and Alternative Medicine

Editorial Service:

1997 - Present Associate Editor, *Urology*

Editorial Review Board

1992 - Present *Urology*

1996 - Present *British Journal of Urology*

1996 - Present *European Urology*

1996 - Present *Journal of Sexual Medicine*

1996 - Present *Journal of Urology*

Other Service:

2013 Scientific Chairman, Baltimore, MD
Medical Research Programs:
Prostate Cancer Research Program, Physical Imaging Panel,
U.S. Army Medical Research and Materiel Command,
Congressionally Directed Medical Research Programs,
Department of Defense

2002 Panel Member, Institute of Medicine, Memphis, TN
Review of Saw Palmetto

2000-2002 Associate Member, National Cancer Institute
Early Detection Research Network, Division of Cancer Prevention

Mentoring:

Medical Students:

2023 - 2025 Shannon Richardson, UCLA DGSOM Class of 2025

2022 - 2023 Mamdouh Aker, UCLA DGSOM Class of 2023, UCLA Urology Resident

2018 - 2022 Jacob Guorgui, UCLA DGSOM Class of 2022, Stanford Surgery Resident

2018 - 2021 Jorge Ballon, UCLA DGSOM Class of 2021, USC Urology Resident

2018 - 2019	Steve Zhou, UCLA DGSOM Class of 2020, Stanford Urology Resident
2015 - 2016	Nima Nassiri, UCLA DGSOM Class of 2016, USC Urology Resident
2012 - 2016	Edward Chang, UCLA DGSOM Class of 2017, UW Urology Resident

Post-Doctoral Scholars:

2015 - 2016	Rory Geohagen, PhD, Biomedical Engineering, UCLA
2013 - 2016	Alan Priester, PhD, Biomedical Engineering, UCLA
2012 – 2013	Shyam Natarajan, PhD, Adjunct Assistant Professor, UCLA

Graduate Students:

2018 - 2024	Jake Pensa, MS Biomedical Engineering, PhD candidate, UCLA
2012 - 2018	Alan Priester, PhD Biomedical Engineering
2013 - 2016	Patricia Lieu, BS Neuroscience, MPH Biostatistics, UCLA
2009 – 2012	Shyam Natarajan, PhD, Adjunct Assistant Professor, UCLA

Urology Residents:

2019 - Present	Ryan J. Chuang, UCLA DGSOM
2018 - 2019	Rajiv Jayadevan, MD, UCLA DGSOM
2017 - 2018	Fuad Elkhoury, MD, UCLA DGSOM
2016 - 2017	Tonye Jones, MD, UCLA DGSOM
2013 - 2016	Jesse Le, MD, UCLA DGSOM

Radiology Resident:

2015 - 2016	Ely Felker, MD, Health Sciences Clinical Professor, UCLA
-------------	--

Urology Fellows:

2021 – 2023	David Kuppermann, MD, Institute of Urologic Oncology, UCLA
2020 – 2021	Wayne Brisbane, MD, Assistant Professor, University of Florida
2019 –2020	Adam Kinnaird, MD MPH, Assistant Professor, University of Alberta
2017 - 2018	Demetrios Simopoulos, Assistant Professor, Johns Hopkins
2016 - 2017	Amir Salmasi, MD, Assistant Clinical Professor, UC San Diego
2015 - 2016	Ray Tang, MD, Assistant Professor, UNC at Chapel Hill
2013 - 2015	Christopher Filson, MD, Assistant Professor, Emory University
2011 - 2013	Geoffery Sonn, MD, Assistant Professor, Stanford University

Junior Faculty:

2013 - 2015	Jim Hu, MD, MPH, Professor of Urology, Cornell University
2013 - 2016	Mitch Kamrava, MD, Radiation Oncology, Cedars-Sinai Medical Center
2013 - 2016	Shyam Natarajan, PhD, Adjunct Assistant Professor, UCLA

Consulting Activities:

2017 - Present	Avenda Health, Founder and Chief Medical Officer
1992 - 2010	Beckman Coulter Corporation
2003 - 2008	Gen-Probe Corporation
2008 - Present	Eigen Corporation
2009 - Present	Hitachi Corporation

HONORS AND AWARDS

Educational Honors:

1969	Alpha Omega Alpha (University of Texas)
1965	Bachelor of Arts with Honors (Tulane University)

Awards:

2017	"Best Video" Award, AUA Annual Meeting in Boston "Focal Laser Ablation: Path to a Clinic Treatment for Prostate Cancer" https://youtu.be/DtLsGfbLSn4
2015	Inaugural Recipient, DeKernion Endowed Chair in Urology, UCLA
2001	Research Award, Early Detection Research Network (EDRN), Division of Cancer Prevention, National Cancer Institute, "Free PSA Molecular Forms (BPSA & proPSA): Biomarker Role", in collaboration with the Brady Urological Institute of Johns Hopkins University
2000	CapCURE (Prostate Cancer Foundation) Research Award, "Biomarker Expression in Benign and Malignant Prostate Tissues of Native Japanese and Japanese-American Men"
1993 & 1994	American Foundation for Urologic Disease (AFUD) Research Awards: "Normalization of Serum PSA levels in Men with Benign Prostatic Hyperplasia: Role of Prostatic Epithelial Quantification"

- 1976 Clinical Research Prize
Grayson Carroll Essay Contest, American Urological Association
"Angiotensin Blockade in Renovascular Hypertension: A controlled, Prospective Study"
- 1976 Resident's Research Prize, Los Angeles Urological Society:
"Angiotensin Blockade in the Rapid Detection of Renovascular Hypertension"

RESEARCH GRANTS

- 2017 - 2024 Principle Investigator, National Cancer Institute, R01 Award
"Focal Laser Ablation of Prostate Cancer Using MRI/US Fusion"
Grant No. R01CA218547-01, \$3.1M
- 2015 - 2017 Principle Investigator, National Cancer Institute, R01 Award
"Prospective Assessment of Image Registration for the Diagnosis of CaP"
Grant No. R01CA195505, \$750K
- 2015 -2016 Principle Investigator
"Focal Laser Ablation of Prostate Cancer: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance"
Medtronic, \$350K
- 2014 - 2015 Principle Investigator
"Refinement of Targeted Biopsy and Active Surveillance,"
Jean Perkins Foundation, \$285K
- 2011 - 2014 Principle Investigator, National Cancer Institute, R01 Award
"Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the Prostate,"
Grant No. R01CA158627, \$1.7M
- 2010 - 2014 Principle Investigator, STAR Trial
"Multicenter Study of HIFU with the Sonablate 500 for the Treatment of Locally Recurrent Prostate Cancer Following Failed External Beam Radiation Therapy Sponsored by USHIFU/ SonaCare Medical, Charlotte, NC, \$185K

INVITED LECTURES AND MAJOR PRESENTATIONS

1. "Prostate Cancer 2017: The Coming Sea Change of Prostate Cancer Care". Simms/Mann UCLA Center for Integrative Oncology, UCLA Medical Center, Los Angeles, CA: September 12, 2017.
2. "It's Not Your Father's Prostate Cancer," Department of Medicine Grand Rounds, UCLA Medical Center, Los Angeles, CA; Jan. 4, 2017
3. "Evolution of Prostate Focal Therapy," Brady Urology Grand Rounds, Weill Cornell Medical College, New York, N.Y.; September 19, 2016
4. "MRI and Guided Biopsy to Improve Dx/Rx of Prostate Cancer," 9th Annual UCSD Urology Postgraduate Course, Del Mar, CA; March 11, 2016
5. "Into the Light: Targeted Biopsy In the Management of Prostate Cancer," Jonsson Cancer Center Research Lecture, UCLA Medical Center, October 15, 2015.
6. "The Sea-Change of Prostate Cancer: Targeted Biopsy and Focal Therapy," Breakthroughs in Medicine and Technology, Jackson Hole, WY; August 1, 2015.

7. "Biopsy Strategy for Focal Therapy," FDA-AUA Workshop, American Urological Association Meeting, New Orleans, LA; May 17, 2015.
8. "MR US Fusion- Guided Prostate Biopsy: Beginner and Advanced Techniques," Course Faculty, American Urologic Association, New York, NY, December 6-7, 2014
9. "Prostate Biopsy via MRI-US Fusion," International Prostate Forum, American Urological Association Meeting, Orlando, FL; May 18, 2014
10. "Innovation: People, Places, and a Story About the Prostate," Guest Speaker, Beckman Coulter Annual Innovations Dinner, Dana Point, CA, *October 10, 2013*.
11. "Targeted Prostate Biopsy via MRI-Ultrasound Fusion," Urology Grand Rounds Presentation, UCI Medical Center, Irvine, CA, *December 10, 2012*.
12. "Prostate cancer 2010; Imaging to Manage Disease Risk." Invited lecture, Focus Session on Prostate Magnetic Resonance Imaging. Radiological Society of North America, Chicago, IL, *November, 2009*.
13. "Dihydrotestosterone (DHT), The Other Androgen. History and Clinical Relevance Today," Urology Grand Rounds Presentation, Johns Hopkins University, Baltimore, MD, *February 2, 2006*.
14. "5 alpha reductase inhibition: history and clinical importance." Featured presentation, Annual Meeting, Canadian Urological Association, Ottawa, Canada, *July, 2005*.
15. "PCA3 Urine Test: Specificity and Improved Prostate Cell Recovery," L.S. Marks, A.W. Partin, S. Brentano, et al. GORDON CONFERENCE, New Frontiers in Cancer Detection and Diagnosis, Buellton, CA, *Jan., 2005*.
16. "The race against time: Issues surrounding andropause." Annual Meeting, American Association of Clinical Chemistry, Los Angeles, CA, *June, 2004*.
17. "BPH and Alpha-blockers, 2004: Alfuzosin, a new treatment." Annual Meeting, Academy of Managed Care Pharmacy, San Francisco, CA, *April, 2004*.
18. "Recent advances in PSA testing," Luminaries Dinner, Hybritech, Inc., Annual meeting, American Urological Association, *2001* (Orlando, FL) and *2002* (Chicago, IL).
19. "Saw Palmetto: Myth and Science." G. Raworth Williams Lecture, Baylor University Hospital, Dallas, TX. *March, 2001*.
20. "Effect of Finasteride and Saw Palmetto Extracts in Men with Symptomatic Benign Prostatic Hyperplasia." 10th annual Congress, Egresados de Los Urologos de Centro Medico Nacional, Mexico City, D.F. *January 1999*

PUBLICATIONS / BIBLIOGRAPHY

A. Research Papers - Peer Reviewed

1. Kishan AU, Valle LF, Marks LS. Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer. *Eur Urol.* 2024 Jan;85(1):47-48. doi: 10.1016/j.eururo.2023.09.018. Epub 2023 Oct 6. PMID: 37805372.
2. Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S, Snyder PJ, Ellenberg SS, Travison TG, Brock GB, Gianatti EJ, van der Schouw YT, Emmelot-Vonk MH, Giltay EJ, Hackett G, Ramachandran S, Svartberg J, Hildreth KL, Antonic KG, Tenover JL, Tan HM, Ho Chee Kong C, Tan WS, Marks LS, Ross RJ, Schwartz RS, Manson P, Roberts SA, Skovsager Andersen M, Velling Magnussen L,

- Aceves-Martins M, Gillies K, Hernández R, Oliver N, Dhilló WS, Bhattacharya S, Brazzelli M, Jayasena CN. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. *Lancet Healthy Longev*. 2023 Oct;4(10):e561-e572. doi: 10.1016/S2666-7568(23)00169-1. PMID: 37804846.
3. Javier-DesLoges J, Dall'Era MA, Brisbane W, Chamie K, Washington SL 3rd, Chandrasekar T, **Marks LS**, Nguyen H, Daneshvar M, Gin G, Kane CJ, Bagrodia A, Cooperberg MR. The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. *Prostate Cancer Prostatic Dis*. 2023 Aug 8. doi: 10.1038/s41391-023-00702-1. Epub ahead of print. PMID: 37553435.
 4. Priester A, Fan RE, Shubert J, Rusu M, Vesal S, Shao W, Khandwala YS, **Marks LS**, Natarajan S, Sonn GA. Prediction and Mapping of Intraprostatic Tumor Extent with Artificial Intelligence. *Eur Urol Open Sci*. 2023 Jun 13;54:20-27. doi: 10.1016/j.euros.2023.05.018. PMID: 37545845; PMCID: PMC10403686.
 5. Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, **Marks LS**. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. *Urol Case Rep*. 2023 Jun 9;50:102461. doi: 10.1016/j.eucr.2023.102461. PMID: 37358989; PMCID: PMC10285561.
 6. Aker MN, Brisbane WG, Kwan L, Gonzalez S, Priester AM, Kinnaird A, Delfin MK, Felker E, Sisk AE, Kuppermann D, **Marks LS**. Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes. *Cancer Med*. 2023 Feb 12. doi: 10.1002/cam4.5692. Epub ahead of print. PMID: 36775929.
 7. Vesal S, Gayo I, Bhattacharya I, Natarajan S, **Marks LS**, Barratt DC, Fan RE, Hu Y, Sonn GA, Rusu M. Domain generalization for prostate segmentation in transrectal ultrasound images: A multi-center study. *Med Image Anal*. 2022 Nov;82:102620. doi: 10.1016/j.media.2022.102620. Epub 2022 Sep 13. PMID: 36148705.
 8. Nassiri N, Richardson S, Kuppermann D, Brisbane WG, Gonzalez S, Kwan L, Felker E, Wallner C, **Marks LS**. Partial Gland Ablation of Prostate Cancer: Effects of Repeat Treatment. *Urology*. 2022 Dec;170:161-167. doi: 10.1016/j.urology.2022.07.024. Epub 2022 Jul 28. PMID: 35907484.
 9. Hudson J, Cruickshank M, Quinton R, Aucott L, Aceves-Martins M, Gillies K, Bhasin S, Snyder PJ, Ellenberg SS, Grossmann M, Travison TG, Gianatti EJ, van der Schouw YT, Emmelot-Vonk MH, Giltay EJ, Hackett G, Ramachandran S, Svartberg J, Hildreth KL, Groti Antonic K, Brock GB, Tenover JL, Tan HM, Kong CHC, Tan WS, **Marks LS**, Ross RJ, Schwartz RS, Manson P, Roberts S, Andersen MS, Magnussen LV, Hernández R, Oliver N, Wu F, Dhilló WS, Bhattacharya S, Brazzelli M, Jayasena CN. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. *Lancet Healthy Longev*. 2022 Jun;3(6):e381-e393. doi: 10.1016/S2666-7568(22)00096-4. PMID: 35711614; PMCID: PMC9184259.
 10. Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER, Sisk AE, Hu JC, **Marks LS**. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. *Eur Urol*. 2022 Jan 31:S0302-2838(22)00010-0. doi: 10.1016/j.eururo.2022.01.008. Epub ahead of print. PMID: 35115177.
 11. **Marks LS**. Prostate Cancer: a comparison of focal therapy and radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2022 Jan 28. doi: 10.1038/s41391-021-00334-3. Epub ahead of print. PMID: 35087221.
 12. Kuppermann D, Calais J, **Marks LS**. Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. *J Urol*. 2022 Apr;207(4):769-778. doi: 10.1097/JU.0000000000002457. Epub 2022 Jan 27. PMID: 35085002.
 13. Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdarie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, **Marks LS**, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ,

- Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ Jr, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. *HGG Adv.* 2022 Jan 13;3(1):100070. doi: 10.1016/j.xhgg.2021.100070. Epub 2021 Nov 19. PMID: 34993496; PMCID: PMC8725988.
14. Kinnaird A, Yerram NK, O'Connor L, Brisbane W, Sharma V, Chuang R, Jayadevan R, Ahdoor M, Daneshvar M, Priester A, Delfin M, Tran E, Barsa DE, Sisk A, Reiter RE, Felker E, Raman S, Kwan L, Choyke PL, Merino MJ, Wood BJ, Turkbey B, Pinto PA, **Marks LS**. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer. *J Urol.* 2022 Apr;207(4):823-831. doi: 10.1097/JU.0000000000002343. Epub 2021 Dec 2. PMID: 34854746.
 15. Liu Y, Zheng H, Liang Z, Miao Q, Brisbane WG, **Marks LS**, Raman SS, Reiter RE, Yang G, Sung K. Textured-Based Deep Learning in Prostate Cancer Classification with 3T Multiparametric MRI: Comparison with PI-RADS-Based Classification. *Diagnostics (Basel).* 2021 Sep 28;11(10):1785. doi: 10.3390/diagnostics11101785. PMID: 34679484; PMCID: PMC8535024.
 16. Kinnaird A, Brisbane W, Kwan L, Priester A, Chuang R, Barsa DE, Delfin M, Sisk A, Margolis D, Felker E, Hu J, **Marks LS**. A prostate cancer risk calculator: Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men. *Can Urol Assoc J.* 2022 Mar;16(3):E161-E166. doi: 10.5489/cuaj.7380. PMID: 34672937; PMCID: PMC8923894.
 17. Cooley LF, Emeka AA, Meyers TJ, Cooper PR, Lin DW, Finelli A, Eastham JA, Logothetis CJ, **Marks LS**, Vesprini D, Goldenberg SL, Higano CS, Pavlovich CP, Chan JM, Morgan TM, Klein EA, Barocas DA, Loeb S, Helfand BT, Scholtens DM, Witte JS, Catalona WJ; Collaborators. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. *J Urol.* 2021 Nov;206(5):1147-1156. doi: 10.1097/JU.0000000000001937. Epub 2021 Sep 10. PMID: 34503355; PMCID: PMC8734323.
 18. Sarma KV, Raman AG, Dhinagar NJ, Priester AM, Harmon S, Sanford T, Mehravand S, Turkbey B, **Marks LS**, Raman SS, Speier W, Arnold CW. Harnessing clinical annotations to improve deep learning performance in prostate segmentation. *PLoS One.* 2021 Jun 25;16(6):e0253829. doi: 10.1371/journal.pone.0253829. PMID: 34170972; PMCID: PMC8232529.
 19. Raman AG, Sarma KV, Raman SS, Priester AM, Mirak SA, Riskin-Jones HH, Dhinagar N, Speier W, Felker E, Sisk AE, Lu D, Kinnaird A, Reiter RE, **Marks LS**, Arnold CW. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer. *J Urol.* 2021 Sep;206(3):595-603. doi: 10.1097/JU.0000000000001832. Epub 2021 Apr 28. PMID: 33908801; PMCID: PMC8903239.
 20. Brisbane WG, Natarajan S, Priester A, Felker ER, Kinnaird A, **Marks LS**. Focal Laser Ablation of Prostate Cancer: An Office Procedure. *J Vis Exp.* 2021 Mar 30;(169). doi: 10.3791/61984. PMID: 33871450.
 21. Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, George AK, Gill IS, Gupta RT, Katz AE, Lebastchi AH, **Marks LS**, Marra G, Pinto PA, Song DY, Sidana A, Ward JF, Sanchez-Salas R, Rosette J, Polascik TJ; Focal Therapy Group Authors. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. *Urol Oncol.* 2021 Nov;39(11):781.e17-781.e24. doi: 10.1016/j.urolonc.2021.01.027. Epub 2021 Mar 4. PMID: 33676851; PMCID: PMC8654321.
 22. Sarma KV, Harmon S, Sanford T, Roth HR, Xu Z, Tetreault J, Xu D, Flores MG, Raman AG, Kulkarni R, Wood BJ, Choyke PL, Priester AM, **Marks LS**, Raman SS, Enzmann D, Turkbey B, Speier W, Arnold CW. Federated learning improves site performance in multicenter deep learning without data sharing. *J Am Med Inform Assoc.* 2021 Jun 12;28(6):1259-1264. doi: 10.1093/jamia/ocaa341. PMID: 33537772; PMCID: PMC8200268.

23. Dhinagar NJ, Speier W, Sarma KV, Raman A, Kinnaird A, Raman SS, **Marks LS**, Arnold CW. Semi-automated PIRADS scoring via mpMRI analysis. *J Med Imaging (Bellingham)*. 2020 Nov;7(6):064501. doi: 10.1117/1.JMI.7.6.064501. Epub 2020 Dec 29. PMID: 33392358
24. Salami SS, Tosoian JJ, Nallandhighal S, Jones Jr TA, Brockman S, Elkhoury FF, Bazzi S, Plouffe KR, Siddiqui J, Liu CJ, Kunju LP, Morgan TM, Natarajan S, Boonstra PS, Sumida L, Tomlins SA, Udager AM, Sisk Jr AE, **Marks LS**, Palapattu GS. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. *Eur Urol*. 2020;S0302-2838(20)30470-X. doi:10.1016/j.eururo.2020.06.041. PMID 32631746
25. Kinnaird A, Sharma V, Chuang R, Priester A, Tran E, Barsa DE, Delfin M, Kwan L, Sisk A, Felker E, **Marks LS**. Risk of Prostate Cancer after a Negative MRI-Guided Biopsy. *J Urol*. 2020;101097JU0000000000001232. doi:10.1097/JU.0000000000001232. PMID 32614257
26. Al Hussein Al Awamlh B, **Marks LS**, Sonn GA, Natarajan S, Fan RE, Gross MD, Mauer E, Banerjee S, Hectors S, Carlsson S, Margolis DJ, Hu JC. Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. *Urol Oncol*. 2020;38(7):637.e9-637.e15. doi:10.1016/j.urolonc.2020.03.019. PMID 32307327
27. Guorgui J, Kinnaird A, Jayadevan R, Priester AM, Arnold CW, **Marks LS**. An Electronic Form for Reporting Results of Targeted Prostate Biopsy: Urology Integrated Diagnostic Report (Uro-IDR). *Urology*. 2020;138:188-193. doi:10.1016/j.urology.2020.01.015. PMID 31978527
28. Chuang RJ, **Marks LS**. Targeted and Systematic Biopsy for Diagnosis and Management of Prostate Cancer. *Clinical Oncology*. 2019 Dec 18. doi: 10.1016/j.clon.2019.11.011. PMID: 31864796
29. Zhou SR, Priester AM, Jayadevan R, Johnson DC, Yang JJ, Ballon J, Natarajan S, **Marks LS**. Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer. *BJU Int*. 2019 Nov 4. doi: 10.1111/bju.14943. PMID: 31680423
30. Zhou SR, Chang E, Patankar A, Huang J, **Marks LS**, Natarajan S. Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men. *J Urol*. 2019 Oct 9. doi: 10.1097/JU.0000000000000587. PMID: 31596671
31. Gross MD, **Marks LS**, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, Hu JC. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian-American Men: A Multicenter Study. 2019 Sep 10. doi: 10.1097/JU.0000000000000534. PMID: 31502942
32. Jayadevan R, Felker ER, Kwan L, Barsa DE, Zhang H, Sisk AE, Delfin M, **Marks LS**. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer. *JAMA Netw Open*. 2019 Sep 4. doi: 10.1001/jamanetworkopen.2019.11019. PMID: 31509206
33. Felker ER, Raman SS, Shakeri S, Mirak SA, Bajgirani AM, Kwan L, Khoshnoodi P, Elkhoury FF, Margolis DJA, Karow D, Lu DSK, White N, **Marks LS**. Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer. *AJR Am J Roentgenol*. 2019 Aug;213(2):365-370. doi: 10.2214/AJR.18.20836. PMID: 31039011
34. Felker ER, Raman SS, Lu DSK, Tuttle M, Margolis DJ, Elkhoury FF, Sayre J, **Marks LS**. Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. *AJR Am J Roentgenol*. 2019 Jul 30;1-6. doi: 10.2214/AJR.19.21637. PMID: 31361529
35. Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, **Marks LS**. Comparison of Targeted vs. Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. *JAMA Surg*. 2019 Jun 12. doi: 10.1001/jamasurg.2019.1734. PMID: 31188412

36. Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, Sadun T, Jayadevan R, Zhou S, Priester AM, Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, **Marks LS**, Reiter RE. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. *Cancer*. 2019 May 1. doi: 10.1002/cncr.32170. PMID: 31042322
37. Jayadevan R, Zhou S, Priester AM, Delfin M, **Marks LS**. Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy. *J Vis Exp*. 2019 Apr 9;(146). doi: 10.3791/59231. PMID: 31033955
38. Jayadevan R, **Marks LS**. Exclusive MRI-targeted biopsy: not so fast. *Lancet Oncol*. 2019 Jan;20(1):9-10. doi: 10.1016/S1470-2045(18)30607-7. PMID: 30470503
39. Priester A, Wu H, Khoshnoodi P, Schneider D, Zhang Z, Asvadi NH, Sisk A, Raman S, Reiter R, Grundfest W, **Marks LS**, Natarajan S. Registration Accuracy of Patient-Specific, Three-Dimensional-Printed Prostate Molds for Correlating Pathology With Magnetic Resonance Imaging. *IEEE Trans Biomed Eng*. 2019 Jan;66(1):14-22. doi: 10.1109/TBME.2018.2828304. PMID: 29993431
40. Simopoulos DN, Sisk AE Jr, Priester A, Felker ER, Kwan L, Delfin MK, Reiter RE, **Marks LS**. Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage. *BJU Int*. 2019 Jan 29. doi: 10.1111/bju.14691. PMID: 30694605
41. van Luijckelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, **Marks LS**, May S, McClure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Waisner EM, Ward JF, Villers A, Ghai S, Fütterer JJ. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. *World J Urol*. 2019 Jan 22. doi: 10.1007/s00345-019-02636-7. PMID: 30671638
42. Zhou SR, Simopoulos DN, Jayadevan R, Felker ER, Delfin MK, Barsa DE, Kwan L, **Marks LS**. Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer. *Urology*. 2019 Jan 16. pii: S0090-4295(19)30058-5. doi: 10.1016/j.urology.2018.11.052. PMID: 30659903
43. Salmasi A, Faiena I, Wu J, Sisk AE Jr, Sachveda A, Vandel JJ, Chamie K, **Marks LS**, Reiter RE. Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. *Urol Oncol*. 2018 Sep;36(9):401.e19-401.e25. doi: 10.1016/j.urolonc.2018.06.006. PMID: 30064933
44. Priester A, Wu H, Khoshnoodi P, Schneider D, Zhang Z, Asvadi NH, Sisk A, Raman S, Reiter R, Grundfest W, **Marks LS**, Natarajan S. Registration Accuracy of Patient-Specific, Three-Dimensional-Printed Prostate Molds for Correlating Pathology With Magnetic Resonance Imaging. *IEEE Trans Biomed Eng*. 2019 Jan;66(1):14-22. doi: 10.1109/TBME.2018.2828304. PMID: 29993431
45. Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE Jr, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, **Marks LS**, Raman SS, Febbo PG, Reiter RE. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. *J Urol*. 2018 Sep;200(3):564-572. doi: 10.1016/j.juro.2018.03.004. PMID: 29524506
46. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, **Marks LS**, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. *J Urol*. 2018 Jun;199(6):1488-1493. doi: 10.1016/j.juro.2017.12.058. PMID: 29307684
47. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, **Marks LS**, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of ⁶⁸Ga-

- PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. *J Nucl Med*. 2018 Mar;59(3):434-441. doi: 10.2967/jnumed.117.202945. PMID: 29242398
48. Elkhoury F, Simopoulos DN, **Marks LS**. MR-guided biopsy and focal therapy: new options for prostate cancer management. *Curr Opin Urol*. 2018 Mar;28(2):93-101. doi: 10.1097/MOU.0000000000000471. PMID: 29232269
 49. Elkhoury F, Simopoulos DN, **Marks LS**. Targeted Prostate Biopsy in the Era of Active Surveillance. *Urology*. 2018 Feb;112:12-19. doi: 10.1016/j.urology.2017.09.007. PMID: 28962878
 50. Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N, Natarajan S, Sharma D, Huang J, Dorey F, **Marks LS**. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? *AJR Am J Roentgenol*. 2017 Dec;209(6):1272-1277. doi: 10.2214/AJR.17.18008. PMID: 28858541
 51. Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, **Marks LS**, Natarajan S. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. *J Urol*. 2018 Feb;199(2):453-458. doi: 10.1016/j.juro.2017.08.085. PMID: 28830754
 52. Chang E, Jones TA, Natarajan S, Sharma D, Simopoulos D, Margolis DJ, Huang J, Dorey FJ, **Marks LS**. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. *J Urol*. 2018 Jan;199(1):98-105. doi: 10.1016/j.juro.2017.07.038. PMID: 28728993
 53. Jones TA, Chin J, Mcleod D, Barkin J, Pantuck A, & **Marks LS**. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. *J Urol*. 2018 Jan;199(1):133-139. doi: 10.1016/j.juro.2017.06.078. PMID: 28652121
 54. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RR, Rettig MB, **Marks LS**, Ahlering TE, Huynh L, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. *J Nucl Med*. 2017 Dec 14. pii: jnumed.117.202945. doi: 10.2967/jnumed.117.202945. PMID: 29242398
 55. Elkhoury FF, Simopoulos DN, **Marks LS**. MR-guided biopsy and focal therapy: new options for prostate cancer management. *Curr Opin Urol*. 2017 Dec 11. doi: 10.1097/MOU.0000000000000471. PMID: 29232269
 56. Elkhoury FF, Simopoulos DN, **Marks LS**. Targeted Prostate Biopsy in the Era of Active Surveillance. *Urology*. 2017 Sep 27. pii: S0090-4295(17)30988-3. doi: 10.1016/j.urology.2017.09.007. PMID: 28962878
 57. Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N, Natarajan S, Sharma D, Huang J, Dorey F, **Marks LS**. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? *AJR Am J Roentgenol*. 2017 Dec;209(6):1272-1277. doi: 10.2214/AJR.17.18008. PMID: 28858541
 58. Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, **Marks LS**, Natarajan S. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. *J Urol*. 2017 Aug 19. doi: 10.1016/j.juro.2017.08.085. PMID: 28830754
 59. Chang E, Jones TA, Natarajan S, Sharma D, Simopoulos D, Margolis DJ, Huang J, Dorey FJ, **Marks LS**. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. *J Urol*. 2017 Jul 18. doi: 10.1016/j.juro.2017.07.038. PMID: 28728993
 60. Jones TA, Chin J, Mcleod D, Barkin J, Pantuck A, **Marks LS**. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. *J Urol*. 2017 Jun 23. doi: 10.1016/j.juro.2017.06.078. PMID: 28652121

61. Simopoulos DN, Natarajan S, Jones TA, Fendler WP, Sisk AE Jr, **Marks LS**. Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance. *Urol Case Rep*. 2017 Jun 3;14:11-14. doi: 10.1016/j.eucr.2017.05.006. PMID: 28607878
62. Goian R, Bernstein AN, McClure TD, Sedrakyan A, Patel NA, Parekh DJ, **Marks LS**, Hu JC. Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review. *J Urol*. 2017 Apr 19. doi: 10.1016/j.juro.2017.03.137. PMID: 28433640
63. Natarajan S, Jones TA, Priester AM, Geoghegan R, Lieu P, Delfin M, Felker E, Margolis DJ, Sisk A, Pantuck A, Grundfest W, **Marks LS**. Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance. *J Urol*. 2017 Apr 7. doi: 10.1016/j.juro.2017.04.017. PMID: 28396184
64. Huen KH, Nseyo U, **Marks LS**. The First Filmed Prostatectomy, 1917: 100 Years of Movies in Urological Education. *Eur Urol*. 2017 Jun;71(6):986-987. doi: 10.1016/j.eururo.2017.02.012. PMID: 28233592
65. Jones TA, **Marks LS**. Re: A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. *Eur Urol*. 2017 Jun;71(6):986-987. doi: 10.1016/j.eururo.2017.02.012. PMID: 28233592
66. Jones TA, Natarajan S, Priester AM, **Marks LS**. Focal Laser Ablation of Prostate Cancer. *Urology*. 2017 Jan;99:e21-e22. doi: 10.1016/j.urology.2016.10.002. PMID: 27720973
67. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, **Marks LS**, Pinto P, Sonn GA, Taneja SS. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. *J Urol*. 2016 Dec;196(6):1613-1618. doi: 10.1016/j.juro.2016.06.079. PMID: 27320841
68. Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, **Marks L**, Pantuck A, Steinberg M, Kamrava M. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. *Brachytherapy*. 2017 Mar - Apr;16(2):299-305. doi: 10.1016/j.brachy.2016.11.002. PMID: 27965117
69. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, **Marks LS**, Catalona WJ. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. *BJU Int*. 2016 Oct 15. doi: 10.1111/bju.13676. PMID: 27743489
70. Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, **Marks LS**. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. *Clin Cancer Res*. 2016 Oct 7. doi: 10.1158/1078-0432.CCR-16-1454. PMID: 28031426
71. Verma S, Rosenkrantz AB, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, **Marks LS**, Pinto P, Sonn GA, Taneja SS. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. *Abdom Radiol (NY)*. 2016 Sep 26. PMID: 27670878
72. Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, Huang J, Grundfest W, **Marks LS**. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. *J Urol*. 2016 Jul 30. pii: S0022-5347(16)30958-2. doi: 10.1016/j.juro.2016.07.084. PMID: 27484386
73. Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, **Marks LS**. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. *J Urol*. 2016 Sep 14. pii: S0022-5347(16)31301-5. doi: 10.1016/j.juro.2016.09.070. PMID: 27639713

74. **Marks LS.** Some prostate cancers are invisible to magnetic resonance imaging! *BJU Int.* 2016 Oct;118(4):492-3. doi: 10.1111/bju.13440. PMID: 27625328
75. Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, **Marks L**, Azzouzi AR, Emberton M. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. *J Urol.* 2016 Oct;196(4):1096-104. doi: 10.1016/j.juro.2016.05.113. PMID: 27291652
76. Mesko S, **Marks L**, Ragab O, Patel S, Margolis DA, Demanes DJ, Kamrava M. Targeted Prostate Biopsy Gleason Score Heterogeneity and Implications for Risk Stratification. *Am J Clin Oncol.* 2016 Jun 8. PMID: 27281263
77. Jones TA, Radtke JP, Hadaschik B, **Marks LS.** Optimizing safety and accuracy of prostate biopsy. *Curr Opin Urol.* 2016 May 20. PMID: 27214580
78. Felker ER, Margolis DJ, Nassiri N, **Marks LS.** Prostate cancer risk stratification with magnetic resonance imaging. *Urol Oncol.* 2016 Mar 31. doi: 10.1016/j.urolonc.2016.03.001. PMID: 27040381
79. Tan HJ, **Marks LS**, Hoyt MA, Kwan L, Filson CP, Macairan M, Lieu P, Litwin MS, Stanton AL. The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer. *J Urol.* 2016 Jun;195(6):1724-30. doi: 10.1016/j.juro.2016.01.108. PMID: 26872841
80. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, Reiter RE, **Marks LS.** Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. *Cancer.* 2016 Mar 15;122(6):884-92. doi: 10.1002/cncr.29874. PMID: 26749141
81. Natarajan S, Raman S, Priester AM, Garritano J, Margolis DJ, Lieu P, Macairan ML, Huang J, Grundfest W, **Marks LS.** Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. *J Urol.* 2015 Dec 31. doi: 10.1016/j.juro.2015.12.083. PMID: 26748164
82. Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, Dorey F, **Marks LS.** Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value. *J Urol.* 2016 May;195(5):1421-7. doi: 10.1016/j.juro.2015.11.055. PMID: 26674305
83. Bockholt N, **Marks LS.** Targeted prostate biopsy using magnetic resonance imaging-ultrasound fusion. *Asian J Androl.* 2015 Nov-Dec;17(6):870-3. doi: 10.4103/1008-682X.151389. PMID: 26289396
84. Rakow-Penner RA, White NS, Margolis DJ, Parsons JK, Schenker-Ahmed N, Kuperman JM, Bartsch H, Choi HW, Bradley WG, Shabaik A, Huang J, Liss MA, **Marks L**, Kane CJ, Reiter RE, Raman SS, Karow DS, Dale AM. Prostate diffusion imaging with distortion correction. *Magn Reson Imaging.* 2015 Nov;33(9):1178-81. doi: 10.1016/j.mri.2015.07.006. PMID: 26220859
85. Nassiri N, Natarajan S, Margolis DJ, **Marks LS.** Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology. *Urology.* 2015 Sep;86(3):432-8. doi: 10.1016/j.urology.2015.07.001. PMID: 26166671
86. Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P, Kupelian PA, **Marks LS.** Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. *Pract Radiat Oncol.* 2015 Nov-Dec;5(6):411-6. doi:10.1016/j.prro.2015.04.006. PMID: 26059510
87. Filson CP, **Marks LS**, Litwin MS. Expectant management for men with early stage prostate cancer. *CA Cancer J Clin.* 2015 Jul-Aug;65(4):265-82. doi: 10.3322/caac.21278. PMID: 25958817
88. **Marks LS.** Significance of Change in Gleason Grade in Patients on Active Surveillance for Prostate Cancer. *J Urol.* 2015 Jul;194(1):8-9. doi: 10.1016/j.juro.2015.04.069. PMID: 25892137

89. Liss MA, White NS, Parsons JK, Schenker-Ahmed NM, Rakow-Penner R, Kuperman JM, Bartsch H, Choi HW, Mattrey RF, Bradley WG, Shabaik A, Huang J, Margolis DJ, Raman SS, **Marks LS**, Kane CJ, Reiter RE, Dale AM, Karow DS. MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. *Front Oncol*. 2015 Feb 17;5:30. doi: 10.3389/fonc.2015.00030. PMID: 25741473
90. Kaplan AL, Ehrlich RM, **Marks LS**, Walsh PC, Bloom DA, Hu JC. Joseph J. Kaufman: renaissance man. *Urology*. 2015 Mar;85(3):487-90. doi: 10.1016/j.urology.2014.10.039. PMID: 25733256.
91. Kamrava M, Hegde JV, Abgaryan N, Chang E, Le JD, Wang J, Kupelian PA, **Marks LS**. Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists? *BJU Int*. 2016 Apr;117(4):584-91. doi: 10.1111/bju.13082. PMID: 25684394
92. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, **Marks LS**, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. The prostate health index selectively identifies clinically significant prostate cancer. *J Urol*. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. PMID: 25463993
93. Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, **Marks LS**, Mozer P, Rastinehad AR, Ahmed HU. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *Eur Urol*. 2015 Jul;68(1):8-19. doi: 10.1016/j.eururo.2014.10.026. PMID: 254546182015
94. Priester A, Natarajan S, Le JD, Garritano J, Radosavcev B, Grundfest W, Margolis DJ, **Marks LS**, Huang J. A system for evaluating magnetic resonance imaging of prostate cancer using patient-specific 3D printed molds. *Am J Clin Exp Urol*. 2014 Jul 12;2(2):127-35. PMID: 25374914
95. **Marks LS**. Significance of Change in Gleason Grade in Patients on Active Surveillance for Prostate Cancer. *J Urol*. 2015 Jul;194(1):8-9. doi: 10.1016/j.juro.2015.04.069. PMID: 25892137
96. Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P, Kupelian PA, **Marks LS**. Multiparametric Magnetic Resonance Imaging for Prostate Cancer Improves Gleason score Assessment in Favorable Risk Prostate Cancer. *Pract Radiat Oncol*. 2015. Jun 6. PMID: 26059510
97. Filson, CP, **Marks L S**, Litwin, MS. Expectant Management for Men with Early Stage Prostate Cancer. *Cancer J Clin*. 2015 May 8. PMID: 25958817
98. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, **Marks LS**, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. The Prostate Health Index (phi) Selectively Identifies Clinically-Significant Prostate Cancer. *J Urol*. 2014 Nov 15. PMID: 25463993
99. Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, **Marks LS**, Mozer P, Rastinehad AR, Ahmed HU. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *Eur Urol*. 2014 Nov 1. PMID: 25454618
100. Partin AW, Van Neste L, Klein EA, **Marks LS**, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. *J Urol*. 2014 Oct;192(4):1081-7. PMID: 24747657
101. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, **Marks LS**, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and Prostate Cancer Detection by Multiparametric Magnetic Resonance Imaging: Correlation with Whole-mount Histopathology. *Eur Urol*. 2014 Sep 22. PMID: 25257029
102. Le JD, Young SN, Macairan M, Margolis DJ, Natarajan S, **Marks LS**. Targeted prostate biopsy with Artemis MRI-ultrasound fusion: how we do it at UCLA. Accepted for publication, *Can J Urology*, 2014.
103. Stephenson SK, Chang EK, **Marks LS**. Screening and Detection Advances in Magnetic Resonance Image-Guided Prostate Biopsy. *Urol Clin North Am*, 2014, May; 41(2): 315-26. PMID: 24725492

104. Sonn GA, Filson CP, Chang E, Natarajan S, Margolis D, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, **Marks LS**. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Accepted for publication, *Urol Oncol*, 2014. Oct; 32(7):952-7. PMID: 25027689
105. **Marks LS**. Improving risk stratification in patients with prostate cancer managed by active surveillance. Invited editorial comment. *British Journal of Urology* 2014. April; 113(4):E13-4. PMID: 24629086
106. Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA, Natarajan S, Dorey FJ, Huang J, Margolis DJA, Reiter RE, **Marks LS**. MRI-ultrasound fusion biopsy for prediction of final prostate pathology. *J Urol*. 2014 Nov;192(5):1367-73. PMID: 24793118
107. Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, and **Marks LS**. Targeted Prostate Biopsy to Select Men for Active Surveillance: Do the Epstein Criteria Still Apply, *J Urol*, 2014, Aug;192(2): 385-90. PMID: 24512956
108. Le JD, Huang J, **Marks LS**. Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. *Asian J Androl*. 2014 Jul-Aug;16(4):522-9. PMID: 24589455
109. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, **Marks LS**. Value of Targeted Prostate Biopsy Using Magnetic Resonance-Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen. *Eur Urol*. (Epub ahead of print) 2013 Mar 17. PMID: 23523537
110. Sonn GA, Margolis DJ, **Marks LS**. Target detection: Magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. *Urol Oncol*. 2013 Nov 13 (Epub ahead of print). PMID: 24239473
111. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb IJ, Hadaschik B, Klotz L, Margolis DJ, **Marks LS**, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y; START Consortium. *Eur Urol*. 2013 Oct;64(4):544-5. PMID: 23537686
112. Albertsen PC, **Marks LS**. MRI Before Prostate Biopsy. *J Urol*. 2013 Dec;190(6):1978-80. PMID: 23994537
113. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, **Marks LS**, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. *Eur Urol*. 2013 Feb;63(2):201-9. PMID: 22854248
114. Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, **Marks LS**, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ. Prospective, Multi-Center Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. *J Urol*. 2013 May;189(5):1702-6. PMID: 23206426
115. Sonn GA, Natarajan S, Margolis D, Macairan M, Lieu P, Huang J, Dorey FJ, **Marks LS**. Targeted Biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. *J Urol*. 2013 Jan; 189 (1): 86-91. PMID: 23158413
116. **Marks LS**, Young S, Natarajan S. MRI-Ultrasound Fusion for Guidance of Targeted Prostate Biopsy. *Curr Opin Urol*. 2013 Jan;23(1):43-50. PMID: 23138468
117. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, **Marks LS**, Pantuck AJ, de la Taille A, Wang G, Mukoyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. *J Transl Med*. 2011 Apr 19;9:43. PMID: 21504557
118. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, **Marks LS**, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. Multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol*. 2011 May;185(5):1650-5. PMID: 21419439

119. Natarajan S, **Marks LS**, Margolis DJ, Huang J, Macairan ML, Lieu P, Fenster A. Clinical Application of a 3D Ultrasound-Guided Prostate Biopsy System. *Urol Oncol*. 2011 May-Jun;29(3):334-42. PMID: 21555104
120. **Marks LS**, Huang J. Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Eur Urol*. 2010 Apr;57(4):727-8. PMID: 20965042
121. Gittelman MC, **Marks LS**, Hill LA, Volinn W, Hoel G. Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies. *Open J Urol*. 2010 Dec 22;3:1-5. PMID: 24198629
122. **Marks LS**, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month Open-Label Extension Study. *Urology*. 2009 Dec;74(6):1318-22. PMID: 19815265
123. **Marks LS**, Kaplan SA. Should Testosterone Replacement Be Given to Men with Large Prostates? *J Urol*. 2009 Nov;182(5):2109-11. PMID: 19758636
124. Isbarn H, Pinthus JH, **Marks LS**, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and Prostate Cancer: Revisiting Old Paradigms. *Eur Urol*. 2009 Jul;56(1):48-56. PMID: 19375844
125. **Marks LS**. Words of Wisdom. Re: Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 prospective Studies. *Eur Urol*. 2009 Mar;55(3):750-1. PMID: 19650234
126. **Marks LS**, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid Efficacy of the Highly Selective Alpha 1A-Adrenoceptor Antagonist Silodosin in Men with Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies. *J Urol*. 2013 Jan;189(1 Suppl):S122-8. PMID: 23234617
127. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, **Marks LS**, Ellis W, Partin AW, Haese A. Prostate Cancer Gene 3 (PCA3): development and Internal Validation of a Novel Biopsy Nomogram. *Eur Urol*. 2009 Oct;56(4):659-67. PMID: 19304372
128. **Marks LS**, Bostwick DG. Prostate Cancer Specificity of PCA3 Gene Testing : Examples from Clinical Practice. *Rev Urol*. 2008 Summer;10(3):175-81. PMID: 18836536
129. Sinha AA, Morgan JL, Betre K, Wilson MJ, **Marks LS**. Cathepsin B Expression in Prostate Cancer of Native Japanese and Japanese-American Patients: an Immunohistochemical Study. *Anticancer Res*. 2008 Jul-Aug;28(4B):2271-7. PMID: 18751406
130. **Marks LS**, Mostaghel EA, Nelson PS. Prostate Tissue Androgens: History and Current Clinical Relevance. *Urology*. 2008 Aug;72(2):247-54. PMID: 18502483
131. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, **Marks LS**, Fradet Y, Rittenhouse H, Groskopf J. PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. *J Urol*. 2008 Apr;179(4):1587-92. PMID: 18295257
132. **Marks LS**, Roehrborn CG, Wolford E, Wilson TH. The Effect of Dutasteride on the Peripheral and Transition Zones of the Prostate and the Value of the Transition Zone Index in Predicting Treatment Response. *J Urol*. 2007 Apr; 177(4):1408-13. PMID: 17382742
133. **Marks LS**, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy. *Urology*. 2007 Mar; 69 (3): 532-5. PMID: 17382159
134. **Marks LS**, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men with Late-Onset Hypogonadism: A Randomized Controlled Trial. *JAMA* 2006 Nov 15;296(19):2351-61. PMID: 17105798
135. Veltri RW, Khan MA, Marlow C, Miller MC, Mikolajczyk SD, Kojima M, Partin AW, **Marks LS**. Alterations in Nuclear Structure and Expression of ProPSA predict Differences Between Native Japanese and Japanese-American Prostate Cancer. *Urology*. 2006 Oct; 68(4):898-904. PMID: 17070389

136. **Marks LS**, , Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. Interpretation of Serum Prostate Specific Antigen Levels in Men Receiving 5 alpha-Reductase Inhibitors: A Review and Clinical Recommendations. *J Urol*. 2006 Sep;176(3):868-74. PMID: 16890642
137. Marberger M, Roehrborn CG, **Marks LS**, Wilson T, Rittmaster RS. Relationship among Serum Testosterone, Sexual Function, and Response to Treatment in Men Receiving Dutasteride for Benign Prostatic Hyperplasia. *J Clin Endocrinol Metab*. 2006 Apr;91(4):1323-8. PMID: 16434455
138. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, **Marks LS**, Rittenhouse H. Aptima PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer. *Clin Chem*. 2006 Jun;52: 1089-1095. PMID: 16627561
139. **Marks LS**, Roehrborn CG, Andriole GL. Prevention of BPH Disease. *J. Urol.*, 2006 Oct: 176: 1299-306. PMID: 16952616
140. **Marks LS**. Use of 5 alpha Reductase Inhibitors in the Prevention of BPH Disease.. *Curr. Urol. Reports*, 2006 Jul(4):293-303. PMID: 16930501
141. **Marks LS**, Nelson PS. Testosterone Supplementation and the Prostate: Review of the Safety Issue. *Curr. Opin. Endocrinol. Diabetes Obesity*. 2006 13:272-277.
142. Roehrborn CG, **Marks LS**, Harkaway R. Enlarged Prostate: A Landmark National Survey of its Prevalence and Impact on U.S. Men and their Partners. *Prostate Cancer Prostatic Dis*. 2006;9(1): 30-34. PMID:16231014
143. Zinner N, Tuttle J, **Marks LS**. Efficacy and Tolerability of Darifenacin, a Muscarinic M3 selective Receptor Antagonist (M3 SRA), Compared with Oxybutinin in Treatment of Patients with Overactive Bladder. *World J. Urol*. 2005 Sep; 23(4):248-52. PMID: 16096831
144. Veltri RW, Park J, Miller MC, **Marks LS**, Kojima M, van Rootselaar C, Khan MA, Partin AW. Stroma-epithelial Measurements of Prostate Cancer in Native Japanese and Japanese-American Men. *Prostate Cancer Prostatic Dis*. 2004; 7(3): 232-7. PMID: 15303120
145. Baker S, Brawley O, **Marks LS**. Untreated Syphilis in Negro Male: A Closure Comes to the Tuskegee Study. *Urology*. 2005 Jun;65(6):1259-62. PMID: 15922414
146. **Marks, LS**. Effect of Dutasteride on the Detection of Prostate cancer in Men with Benign Prostatic Hyperplasia (editorial comment), G.L. Andriole, et al, *Urolog*. 2004 Sep;64(3): 537-41. PMID: 15351586
147. **Marks, LS**. 5 Alpha Reductase: History and Clinical Importance. *Rev Urol*. 2004;6 (Suppl 9): S 11-21. PMID: 16985920
148. **Marks LS**, Kojima M, Demarzo AM, et al. Prostate Cancer in Native Japanese and Japanese-American Men: Effects of Dietary Differences on Prostate Tissues. *Urology*. 2004 Oct; 64(4): 765-71. PMID: 15491717
149. Roehrborn CG, **Marks LS**, Fenter TC, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. *Urology*. 2004 Apr; 63(4): 709-15. PMID: 15072886
150. **Marks LS**. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant. *Urology* 2003 Dec 22; 62 (6 Suppl 1):36-42. PMID: 14706507
151. Partin AW, Roehrborn CG, Lieber MM, and **Marks LS**. PSA as a biomarker for benign prostatic hyperplasia disease progression. *Advanced Studies in Medicine of Johns Hopkins University* 3 (4D): S347-61, 2003.
152. **Marks LS**, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. *Urology* 2003 Nov;62(5):888-93. PMID: 14624914
153. **Marks LS**. Treatment of men with minimally symptomatic benign prostatic hyperplasia--PRO: the argument in favor. *Urology*. 2003 Nov;62(5):781-3. PMID: 14624893
154. **Marks LS**, Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varnese L, and Rosen R. Efficacy of tadalafil for treatment of erectile dysfunction at 24 and 36 hours after dosing. *Urology*. 2003 Jul; 62(1):121-5. PMID: 12837435

155. Veltri RW, **Marks LS**, Miller MC, Bales WD, Fan J, Macairan ML, Epstein JI, Partin AW. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. *Urology*. 2002 Oct;60(4):617-22. PMID: 12385921
156. **Marks LS**, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders Jr. FE, Pantuck AJ and Tyler VE. PC-SPES: herbal formulation for prostate cancer. *Urology*. 2002 Sep; 60(3): 369-75. PMID: 12350462
157. Harry J. Linton, **Leonard S. Marks**, Lisa S. Millar, Christine L. Knott, Harry G. Rittenhouse, Stephen D. Mikolajczyk. Benign prostate-specific antigen (BPSA) , a subform of free prostate specific antigen in serum, is elevated in men with benign prostate disease. *Clin Chem* 2003 Feb;49(2):253-9. PMID: 12560348
158. Mikolajczyk SD, **Marks LS**, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. *Urology*. 2002 Jun;59(6):797-802. PMID: 12031356
159. **Marks LS**, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. *Urology*. 2001 May; 57(5): 999-1005. PMID: 11337315
160. **Marks LS**, Epstein JI, Partin, AW. The role of prostate needle biopsy in evaluation of chemopreventive agents. *Urology*. 2001 Apr; 57(4 Suppl 1): 191-3. PMID: 11295625
161. Partin AW and **Marks LS**. Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents. *Urology*. 2001 Apr; 57(4 Suppl 1): 132-6. PMID: 11295611
162. **Marks LS**, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garriss JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. *J Urol*. 2000 May; 163(5): 1451-6. PMID: 10751856
163. Simon I, Snow PB, **Marks LS**, Christens-Barry WA, Epstein JI, Bluemke DA, Partin AW. Neural network prediction of prostate tissue composition based on MRI analysis. *Anal Quant Cytol Histol*. 2000 Dec; 22(6): 445-52. PMID: 11147298
164. Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, **Marks LS**, and Slawin KM. Seminal plasma contains "BPSA," a molecular form of prostate specific antigen that is associated with benign prostatic hyperplasia. *Prostate*. 2000 Nov 1;45(3): 271-6. PMID: 11074531
165. **Marks LS**. The fundamental concept, that interindividual differences among prostate glands can explain varying responses to treatment, remains intact. A simple test to pinpoint those differences remains the challenge. *Urology*. 2000 Aug 1;56(2): 266. PMID: 10925091
166. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, **Marks LS**, Song W, Wheeler TM, and Slawin KM. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. *Cancer Res*. 2000 Feb 1; 60(3): 756-9. PMID: 10676664
167. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Wolfert RL, **Marks LS**, Song W, Wheeler TM, Slawin KM. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. *Urology*. 2000 Jan; 55(1): 41-5. PMID: 10654892
168. **Marks LS**, Ettekal B, Cohen MS, Macairan ML, Vidal J. Use of a shape-memory alloy (nitinol) in a removable prostate stent. *Tech Urol*. 1999 Dec; 5(4): 226-30. PMID: 10591265
169. Mikolajczyk SD, Millar LS, Marker KM, Rittenhouse HG, Wolfert RL, **Marks LS**, Charlesworth MC, Tindall DJ. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. *Cancer Res*. 1999 Aug 15;59(16): 3927-30. PMID: 10463585
170. **Marks LS**, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garriss JB, Macairan ML, Shery ED, Santos PB, Stoner E, deKernion JB. Long-term effects of finasteride on prostate tissue composition. *Urology*. 1999 Mar;53(3): 574-80. PMID: 10096387
171. **Marks LS** and Tyler VE. Saw palmetto extract: Newest (and oldest) treatment for men with Symptomatic Benign Prostatic Hyperplasia. *Urology*. 1999 Mar; 53(3): 457-61. PMID: 10096366

172. **Marks LS**, Duda C, Dorey FJ, Macairan ML, and Santos PB. Treatment of erectile dysfunction with sildenafil (Viagra). *Urology* 53: 19-24, 1999. NOTE: 1st article in this journal to be electronically posted with full text and graphics: <http://www-east.elsevier.com/url/>.
173. Epstein JI, Partin AW, Shue M, Sherry ED, **Marks LS**. Histological changes in benign prostate biopsies following long-term, finasteride therapy for benign prostatic hyperplasia. *J Urol Path* 10: 87-95, 1999.
174. Pannek J, **Marks LS**, Pearson JD, Rittenhouse HG, Chan DW, Shery ED, Gormley GJ, Subong ENP, Kelley CA, Stoner E, and Partin AW. Influence of Finasteride on Free and Total Serum Prostate Specific Antigen Levels in Men with Benign Prostatic Hyperplasia. *J Urol*. 159: 449-53, 1998. PMID:9649261
175. **Marks LS**, Dorey FJ, Macairan ML, Park C, and deKernion JB. 3-D Ultrasound Device for Rapid Determination of Bladder Volume. *Urology* 50: 341-8, 1997. PMID:9301695
176. **Marks LS**, Partin AW, Gormley GJ, Dorey FJ, Shery ED, Garriss J, deKernion JB, and Stoner E. Prostate Tissue Composition and Response to Finasteride vs. Placebo in Men with Symptomatic BPH. *J Urol*. 157:2171-8, 1997. PMID: 9146609
177. **Marks LS**, Penson D, Maller J, Nielsen RT, and deKernion JB. Computer-generated graphical presentations: Use of multimedia to enhance communication. *Urology* 49: 2-9, 1997. PMID: 9000177
178. **Marks LS**, Dorey FJ, Rhodes T, Shery ED, Rittenhouse HG, Partin AW, and deKernion JB. Serum PSA levels after TURP: Longitudinal characterization in men with BPH. *J Urol*. 156: 1035-9, 1996. PMID:8709302
179. **Marks LS**, Treiger B, Dorey FJ, and Shery ED. Prostatic aperture resulting from visual laser ablation (VLAP): Classification system based on follow-up endoscopy. *J Endourol*. 9: 175-81, 1995. PMID: 7543329
180. **Marks LS**, Dorey FJ, Treiger B, FU YS, and deKernion JB. Morphometry of the Prostate: I. Distribution of tissue components in hyperplastic glands. *Urology* 44: 486-92, 1994. PMID:7524234
181. **Marks LS**. Serial Endoscopy following Visual Laser Ablation of Prostate (VLAP). *Urology* 42: 66-71, 1993. PMID:7687080
182. **Marks LS**. Value of balloon dilation in treatment of youthful patients with prostatism. *Urology* 39: 31-8, 1992. PMID:1370248
183. Gillespie L, Ehrlich RM, **Marks LS**, Maxwell MH, and Kaufman JJ. Use of saralasin test to detect renovascular hypertension in childhood. *Urology* 16: 453-6, 1980.
184. Zawada ET Jr, Maxwell MH, **Marks LS**, Lee DB, Kaufman JJ. The diagnostic and therapeutic uses of saralasin in renal transplant hypertension. *J Urol*. 123: 148-52, 1980. PMID:6986475
185. Zawada ET, Dornfeld L, Maxwell MH, **Marks LS**, and Kaufman JJ. Pheochromocytoma and vasodepressor response to saralasin. *Annals of Internal Medicine* 91: 494, 1979.
186. Walther PJ, **Marks LS**, Stern D, and Smith RB. Renal metastasis from adenocarcinoma of the lung: Massive hematuria managed by therapeutic embolization. *J Urol*. 122: 398-400, 1979. PMID:470021
187. **Marks LS** and Maxwell MH. Tigerstedt and the discovery of renin: An historical note. *Hypertension* 1: 384-8, 1979. PMID:396241
188. Maxwell MH and **Marks LS**. Angiotensin blockade by saralasin bolus injection. *Kidney Int Suppl*. 15: S53-9, 1979. PMID: 289864
189. Kaufman JJ, **Marks LS**, Maxwell MH. Renovascular hypertension: 1979. *Surg Annu*. 11: 313-61, 1979. PMID: 11905903
190. Maxwell MH, Varady P, Zawada ET, Burkhalter JF, Waks U, and **MarksLS**. Maximal discrimination of renovascular from essential hypertension by the saralasin test. *Clin Sci Molec Med* 55: S297-299, 1978. PMID: 282071
191. Maxwell MH, **Marks LS**, Lupu AN, Cahill PJ, Franklin SS, Kaufman JJ. Predictive value of rennin determinations in renal artery stenosis. *JAMA* 238: 2617-20, 1977. PMID: 579197
192. **Marks LS**, Maxwell MH, and Kaufman JJ. Renin, sodium, and vaso-depressor response to saralasin in renovascular and essential hypertension. *Annals of Internal Medicine* 87: 176-82, 1977. PMID: 889198

193. Barajas L, **Marks LS**, and Trygstad C. Unilateral renal hypoplasia with associated venous anomaly and hypertension. *Virchows Arch A Pathol Anat Histol*. 374: 169-82, 1977. PMID: 141787
194. **Marks LS**, Maxwell MH, Gross C, Waks U, and Kaufman JJ. Angiotensin blockade in renovascular hypertension: A controlled, prospective study. *British Journal of Urology* 49: 181-8, 1977. PMID: 334316
195. **Marks LS**, Maxwell MH, and Kaufman JJ. Non-renin-mediated renovascular hypertension: A new syndrome? *Lancet* 1: 615-7, 1977. PMID: 66424
196. **Marks LS**, Waisman J, Longmire WP, Maxwell MH, and Goodwin WE. Renal artery repair: Normal blood pressure and renal function 20 years later. *JAMA*. 236: 1972-3, 1976. PMID: 989562
197. **Marks LS**, Maxwell MH, Smith RB, Cahill PA, and Kaufman JJ. Detection of renovascular hypertension: Saralasin test versus renin determinations. *J Urol* 116: 406-9, 1976. PMID: 1053323
198. **Marks LS**, Maxwell MH, Varady PD, Lupu AN, and Kaufman JJ. Renovascular hypertension: Does the renal vein renin test predict operative results? *J Urol* 115: 365-8, 1976. PMID: 1263307
199. **Marks LS**, Maxwell MH, Waks U, and Kaufman JJ. Angiotensin blockade as a rapid diagnostic test in hypertension. *Proc Eur TranspDialysis Assn* 13: 506, 1976.
200. Maxwell MH, **Marks LS**, Varady PD, Lupu AN, and Kaufman JJ. Renal vein renin in essential hypertension. *J of Lab Clin Med* 86: 901-9, 1975. PMID: 1194755
201. **Marks LS**, Maxwell MH, and Kaufman JJ. Saralasin bolus test: Rapid screening procedure for reninmediatedhypertension. *Lancet* 2: 784-7, 1975. PMID: 78152
202. **Marks LS** and Maxwell MH. Renal vein renin: Value and limitations in the prediction of operative results. *Urol ClinN Am* 2: 311-25, 1975. PMID: 1154554
203. **Marks LS**, Smith RB, and Kaufman JJ. Renal artery stenosis and coexisting retroperitoneal lesions. *Rounds, The Journal of the Wadsworth Hospital* 16: 33, 1975.
204. **Marks LS**. Vesico-ureteral reflux from foreign body bladder calculus. *Journal of Urology* 112: 516-8, 1974. PMID: 4416865
205. **Marks LS**, Smith RB, and Kaufman JJ. The renal hypertensive suspect with coexistent lesions. *Urology* 4: 140-4, 1974. PMID: 4855053
206. Kaufman JJ, **Marks LS**, and Smith RB. Stenosis of the renal artery and coexistent lesions. *Surgery, Gynecology, and Obstetrics* 139: 59-64, 1974. PMID: 4834278
207. **Marks LS**, Brosman SA, Lindstrom RR, and Fay R. Arteriography in penetrating renal trauma. *Urology* 3: 18-22, 1974. PMID: 4812892
208. Poutasse EF, **Marks LS**, Wisoff CP, Vinson AM, and Wan AT. Renal vein renin determinations in hypertension: Falsely negative tests. *J Urol* 110: 371-4, 1973. PMID: 4742170
209. **Marks LS** and Poutasse EF. Renin measurements: Use in evaluation of the renal hypertensive suspect. *Virginia Medical Monthly* 100: 228-34, 1973. PMID: 4688405
210. **Marks LS** and Poutasse EF. Hypertension from renal tuberculosis: Operative cure predicted by renal vein renin. *J Urol* 109: 149-51, 1973. PMID: 4685720
211. **Marks LS** and Gallo DA. Ureteral obstruction in the patient with prostatic carcinoma. *Brit J Urol* 44: 411-6, 1972. PMID:5070145
212. **Marks LS** and Kolmen SN. Tween 20 shock in dogs and related fibrinogen changes. *Am J Physiol* 220: 218-21, 1971. PMID: 4395140
213. **Marks LS** and Kolmen SN. Release of stored fibrinogen in histamine shock. *Texas Reports in Biology and Medicine* 25: 488, 1967.

B. Research Papers - Peer Reviewed (Submitted)

None

C. Research Papers - Non-Peer Reviewed

None

D. Research Papers - Non-Peer Reviewed (In Press)

None

E. Research Papers - Non-Peer Reviewed (Submitted)

None

F. Papers in Preparation (Research Completed)

None

G. Letters to the Editor

None

H. Reviews

None

I. Editorials

None

J. Abstracts

1. Zhou SR, Jayadevan R, Felker ER, Delfin MK, Barsa, DE, **Marks LS**. Hemi-gland Cryoablation of Prostate Cancer with MRI-Guided Biopsy for Evaluation and Follow-up: Update on 18-Month Cancer Control. Accepted as a podium presentation at the Western AUA Annual Meeting in November 2019, Monterey, CA.

BOOK CHAPTERS

1. Jones TJ, Natarajan S, and **Marks LS**. Focal Laser Ablation for Carcinoma of Prostate. Chapter in Smith's Textbook of Endourology, 4th Edition, Wiley-Blackwell, Publisher; London, 2017.
2. **Marks, LS**: Beyond PSA: Promising New Markers for Prostate Cancer. In Management of Prostate Cancer, Klein, E.A. and Jones A.S., editors. Springer, 2012. New York, pp. 51-77.
3. **Marks, LS**: Renovascular Hypertension. In Current Urologic Therapy, Kaufman, J.J., editor. W.B. Saunders Co., 1980. Philadelphia, pp. 156-160.
4. Kaufman, JJ, **Marks, LS**, and Maxwell, MH: Renovascular Hypertension. In Surgery Annual '79, Nyhus, L.M., editor. Appleton-Century-Crofts, New York, pp. 313-361.

5. **Marks, LS** and Kaufman, JJ: Renovascular Hypertension. In Urology, Karafin, L. and Kendall, A.R. (eds.). Harper and Row, Hagerstown, Maryland, 1978.

JURIED VIDEOS

1. "Focal Laser Ablation: Path to a Clinic Treatment for Prostate Cancer," Annual Meeting, American Urological Association, Boston, MA; May 2017.
2. "Use of MRI/US Fusion for Targeted Prostate Biopsy in Active Surveillance," Annual Meeting, American Urological Association, Best in Class Award, Orlando, FL; May 19, 2014.